OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 7.01 EUR -0.71% Market Closed
Market Cap: 152.5m EUR
Have any thoughts about
OSE Immunotherapeutics SA?
Write Note

OSE Immunotherapeutics SA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Income from Continuing Operations
€46m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Income from Continuing Operations
€17.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Income from Continuing Operations
-€34.1m
CAGR 3-Years
-62%
CAGR 5-Years
N/A
CAGR 10-Years
-13%
G
Genfit SA
PAR:GNFT
Income from Continuing Operations
€22.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Income from Continuing Operations
-€102m
CAGR 3-Years
-35%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Income from Continuing Operations
€6.6m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
152.6m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
28.11 EUR
Undervaluation 75%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Income from Continuing Operations?
Income from Continuing Operations
46m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Income from Continuing Operations amounts to 46m EUR.

Back to Top